March 23, 2015 3:35 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Monday, Jefferies analysts maintained a Buy rating on
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NYSE: JNS), while raising the price target from $20 to $21, after a visit to the company's headquarters last week.Janus Capital's performance has continued to improve, with its equity franchise up about 5.3% year-to-date. This is likely to "translate into continued flow momentum," the analysts said, while adding, "Notably, following several years of net outflows in its retail equity franchise, JNS has been net positive in each of the last 3 months (~ +$500M total)."While on one hand the company faces a deceleration in retail momentum, the institutional interest has not been exciting. "Finally, while hard to quantify, there appears to have been a knock-on effect with respect to the pre-existing fixed income platform as consultants and inst'l clients look to gain comfort with the structure," the report mentioned. The fixed income inflow estimate for 2016 was reduced from $24B to $8B, while the equity inflow assumption was raised from $5B to $10B. The equity franchise across a number of products, especially Global Life Sciences, Contrarian, Enterprise, Venture, and Triton, has been delivering a strong relative performance. These appear "well positioned to continue competing for share," the analysts commented. "Amongst its peers, JNS represents one of the few positive active equity organic growth stories with improving fundamentals. In addition, JNS has increasing flexibility with its excess cash flow which we believe will be increasingly allocated to share repurchases," the analysts added.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.